Japanese Encephalitis (JE) is a mosquito-borne viral infection that primarily affects the brain and can lead to severe neurological complications and death.
Though preventable, it continues to be a major public health concern across several Asian countries, including India.
Every monsoon, outbreaks remind us of the urgent need for awareness, vaccination, and preventive measures—especially in rural and peri-urban regions where humans, pigs, and mosquitoes coexist closely.
1. Epidemiology in India
Japanese Encephalitis is caused by the Japanese Encephalitis Virus (JEV), a flavivirus related to dengue, yellow fever, and West Nile virus.
It is endemic in 24 states and Union Territories of India, with the highest burden reported from Uttar Pradesh, Bihar, Assam, West Bengal, and Tamil Nadu.
The first major outbreak In India was reported in 1955 in Vellore, Tamil Nadu, but since then, recurrent epidemics have been noted across the country—particularly in northeastern and northern states.
The National Vector Borne Disease Control Programme (NVBDCP) estimates that India contributes nearly 50% of the global JE cases.
The disease is seasonal, peaking during and after the monsoon months (July to December in northern India, and May to October in southern India).
Children below 15 years are most affected because of lower immunity, although adults can also develop the disease in areas where the virus is newly introduced.
Environmental factors like paddy cultivation, pig rearing, stagnant water bodies, and climatic conditions favoring mosquito breeding have made JE endemic in several rural districts.
2. Transmission and Life Cycle
JE is transmitted by the bite of infected Culex mosquitoes, mainly Culex tritaeniorhynchus and Culex vishnui.
These mosquitoes breed in rice fields, ponds, and irrigation canals, making agricultural communities particularly vulnerable.
The natural cycle of the virus involves:
– Mosquitoes (vectors)
– Wading birds (reservoir hosts, particularly ardeid birds like herons and egrets)
– Pigs (amplifying hosts)
Humans are “dead-end hosts”, meaning they do not develop high enough levels of the virus in their blood to infect mosquitoes further.
Thus, person-to-person transmission does not occur.
The mosquito typically bites in the evening and night, and a single infected mosquito can infect multiple individuals in one cycle.
Climate change, deforestation, and unplanned urbanization are expanding mosquito habitats, increasing the risk of transmission even in
previously low-risk areas.
3. Clinical Features and Symptoms
The incubation period is usually 5 to 15 days after the mosquito bite. Most infections (over 99%) are asymptomatic or mild, but a small percentage develop severe illness with high fatality.
Stages and Symptoms:
1. Prodromal Stage (1–3 days):
– Sudden onset of fever, headache, vomiting
– Malaise, abdominal pain
– May be mistaken for common viral fever
2. Acute Encephalitic Stage (3–7 days):
– High-grade fever, neck stiffness
– Seizures, especially in children
– Altered sensorium, confusion, coma
– Movement disorders, involuntary jerks, parkinsonian features
– In severe cases, respiratory distress due to brainstem involvement
3. Late Stage and Sequelae:
Even with recovery, about 30–50% develop neurological or psychiatric sequelae such as:
– Cognitive impairment
– Behavioral abnormalities
– Speech difficulties
– Motor deficits (spasticity, tremors)
– Learning disabilities in children
The case fatality rate ranges from 20–30% despite treatment, highlighting the importance of prevention.
4. Diagnosis
Early diagnosis is crucial for case management and outbreak control.
In India, diagnostic facilities are available through Integrated Disease Surveillance Programme (IDSP) and designated sentinel laboratories.
Common diagnostic tests:
IgM antibody capture ELISA (MAC-ELISA): Gold standard; detects JEV-specific IgM antibodies in serum or cerebrospinal fluid (CSF)
CSF analysis: Shows pleocytosis (increased lymphocytes), mild protein elevation
Neuroimaging (MRI/CT): May show thalamic, basal ganglia, and brainstem lesions typical of JE
Differential diagnosis includes dengue encephalitis, herpes encephalitis, cerebral malaria, and tuberculous meningitis.
5. Management
There is no specific antiviral treatment for JE. Management is supportive and symptomatic, focusing on:
– Hospitalization for close monitoring
– Fever control with antipyretics
– Seizure management with anticonvulsants
– Airway protection and ventilation in severe cases
– Nutritional and fluid support
– Rehabilitation—physiotherapy, occupational therapy, and speech therapy—plays a crucial role in improving long-term outcomes in patients with neurological sequelae.
– Antibiotics or antivirals are not effective against JE virus. However, empirical treatment for bacterial meningitis or malaria is often initiated until diagnosis is confirmed.
6. Prevention and Control
Prevention of JE revolves around vector control, animal management, public awareness, and most importantly, vaccination.
A. Vector Control
– Source reduction: Removing stagnant water, clearing drainage channels
– Larval control: Using larvicidal agents or biological control like Gambusia fish
– Personal protection: Mosquito repellents, insecticide-treated bed nets, full-sleeve clothing
– Fogging/spraying: In outbreak situations under NVBDCP guidelines
B. Animal Husbandry Measures
– Pig rearing should be kept away (at least 500 meters) from human dwellings
– Mosquito-proof pig shelters
– Regular veterinary surveillance for pigs and birds
C. Community Awareness
Health education about symptoms, prevention, and vaccination is essential—especially in endemic rural districts where myths and lack of awareness delay treatment.
7. Vaccination: The Cornerstone of Prevention
Vaccination remains the most effective strategy for controlling JE in India.
Under the Universal Immunization Programme (UIP), JE vaccination is provided in endemic districts across 24 states.
Types of Vaccines Available in India
1. Live Attenuated SA 14-14-2 Vaccine
Derived from an attenuated strain of JEV
Administered subcutaneously
Schedule:
1st dose at 9 months (along with measles), 2 nd dose at 16–24 months (along with DPT booster)
In endemic districts, mass vaccination campaigns target children aged 1–15 years Highly effective and safe with >95% seroconversion
2. Inactivated Vero Cell-Derived Vaccines
– Used in adults and travelers to endemic areas
– Two doses given 28 days apart
– Vaccine Coverage and Challenges
Despite inclusion in UIP, vaccine coverage varies across states. Challenges include:
– Poor community awareness
– Logistical issues in rural areas
– Missed second doses
– Migration and poor record-keeping
Intensified immunization drives and school-based vaccination programs have improved coverage, but sustained political and community engagement is essential.
8. Indian Public Health Efforts
The National Programme for Prevention and Control of Japanese Encephalitis/Acute Encephalitis Syndrome (JE/AES) was launched in 2014 to integrate efforts in:
– Early case detection and referral
– Strengthening diagnostic laboratories
– Vector control activities
– Rehabilitation for affected children
Intersectoral coordination with animal husbandry and rural development departments District-level surveillance and mapping have helped identify high-risk areas for targeted interventions.
States like Assam and Uttar Pradesh have successfully reduced case fatality rates through improved awareness, vaccination, and treatment facilities.
9. The Road Ahead
Japanese Encephalitis remains a preventable but persistent cause of child mortality and disability in India.
Strengthening primary healthcare, ensuring universal vaccine coverage, and integrating vector control with environmental management are key to long-term elimination.
The lessons from JE control extend beyond this disease—they remind us that zoonotic infections thrive at the intersection of humans, animals, and environment, and combating them requires a one Health approach involving multiple sectors.
Conclusion:
Japanese Encephalitis continues to challenge India’s public health system, but progress is evident.
With effective vaccination, improved diagnostics, and community awareness, we can move toward a future where no child suffers from this preventable neurological disease.
Prevention is truly better than cure—especially when the cure doesn’t exist.
I wasn’t aware of this. Good article